Rocketing sales, reduced costs shrink AFT Pharmaceuticals’ loss
AFT Pharmaceuticals reports reduced losses in latest results.
Thu, 22 Nov 2018
AFT Pharmaceuticals' sales have doubled and its first half-year loss has shrunk compared to the same period last year.
The New Zealand company, which manufactures the painkiller Maxigesic, reported losses of $109,000 for the six months to September 2018. The first-half loss is down from -$6.7
Want to read more? It's easy.
Choose your best value subscription option
Individual
Group membership
NBR Marketplace
Yearly Premium Online Subscription
NZ$499.00 / yearly
Monthly Premium Online Subscription
NZ$44.95 / monthly
Smartphone Only Subscription
NZ$24.95 / monthly
Premium Group Membership 10 Users
NZ$350+GST / monthly
$35 per user - Pay by monthly
credit card debit
Premium Group Membership 20 Users
NZ$600+GST / monthly
$30 per user - Pay by monthly
credit card debit
Premium Group Membership 50 Users
NZ$1250+GST / monthly
$25 per user - Pay by monthly
credit card debit
Premium Group Membership 100 Users
NZ$1875+GST / monthly
$18.75 per user - Pay by monthly
credit card debit
